Comparar métodos

	Qualidade de Vida em Epilepsia-89 (QOLIE-89)	Escala de Rankin Modificada (mRS)	Escala de Qualidade de Vida Específica para AVC (SS-QoL)
Área	Neurologia	Neurologia	Neurologia
Família	Process / pipeline	Process / pipeline	Process / pipeline
Ano de origem	1995	1988	1999
Autor original	Orrin Devinsky, NYU	Rankin scale original (Rankin, 1957); modified version by van Swieten et al.	Lee S. Williams, Indiana University
Tipo	Self-report questionnaire	Clinician-rated ordinal scale	Self-report questionnaire
Fonte seminal	Devinsky, O., Vickrey, B. G., Cramer, J., Edwards, B., Perrine, K., Hamberger, M. J., & Towle, V. L. (1995). Development of the Quality of Life in Epilepsy Inventory. Epilepsia, 36(11), 1089-1104.	van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.	Williams, L. S., Weinberger, M., Harris, L. E., Clark, D. O., & Biller, J. (1999). Development of a Stroke-Specific Quality of Life Scale. Stroke, 30(7), 1362-1369.
Outros nomes	QoLIE-89	mRS, Rankin Scale, Modified Rankin	Stroke-Specific QoL, SS-QOL
Relacionados	3	4	4
Resumo	The QOLIE-89 is a comprehensive disease-specific quality-of-life instrument developed specifically for people with epilepsy. Introduced by Devinsky and colleagues in 1995, it captures the broad impact of epilepsy on physical, emotional, social, and cognitive functioning. With 89 items organized into 17 distinct domains, it remains one of the most detailed QoL assessments for epilepsy and is widely used in clinical trials, health services research, and outcome monitoring.	The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials.	The SS-QoL is a disease-specific quality-of-life instrument designed to capture the multidimensional impact of stroke on survivors' functional and emotional well-being. Developed by Williams and colleagues in 1999, this 49-item scale addresses stroke-specific concerns including language, cognition, mobility, and emotional functioning. It is a gold-standard instrument for stroke outcome research and routine clinical monitoring of post-stroke recovery.